Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice.

Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's and Papworth Hospitals, Cambridge, United Kingdom.
Circulation Research (Impact Factor: 11.09). 04/2006; 98(6):818-27. DOI: 10.1161/01.RES.0000215809.47923.fd
Source: PubMed

ABSTRACT Heterozygous germline mutations in the gene encoding the bone morphogenetic protein type II (BMPR-II) receptor underlie the majority (>70%) of cases of familial pulmonary arterial hypertension (FPAH), and dysfunction of BMP signaling has been implicated in other forms of PAH. The reduced disease gene penetrance in FPAH indicates that other genetic and/or environmental factors may also be required for the clinical manifestation of disease. Of these, the serotonin pathway has been implicated as a major factor in PAH pathogenesis. We investigated the pulmonary circulation of mice deficient in BMPR-II (BMPR2(+/-) mice) and show that pulmonary hemodynamics and vascular morphometry of BMPR2(+/-) mice were similar to wild-type littermate controls under normoxic or chronic hypoxic (2- to 3-week) conditions. However, chronic infusion of serotonin caused increased pulmonary artery systolic pressure, right ventricular hypertrophy, and pulmonary artery remodeling in BMPR2(+/-) mice compared with wild-type littermates, an effect that was exaggerated under hypoxic conditions. In addition, pulmonary, but not systemic, resistance arteries from BMPR2(+/-) mice exhibited increased contractile responses to serotonin mediated by both 5-HT2 and 5-HT1 receptors. Furthermore, pulmonary artery smooth muscle cells from BMPR2(+/-) mice exhibited a heightened DNA synthesis and activation of extracellular signal-regulated kinase 1/2 in response to serotonin compared with wild-type cells. In vitro and in vivo experiments suggested that serotonin inhibits BMP signaling via Smad proteins and the expression of BMP responsive genes. These findings provide the first evidence for an interaction between BMPR-II-mediated signaling and the serotonin pathway, perturbation of which may be critical to the pathogenesis of PAH.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple abnormalities of bone morphogenetic protein (BMPs) signaling are implicated in the process of pulmonary arterial hypertension (PAH). BMP4 plays an important role during the process of pulmonary arterial remodeling and mutant of the principle BMP4 receptor, BMP receptors II (BMPRII), is found to associate with the development of PAH. However, the likely mechanism defining the contribution of BMPRII to BMP4 mediated signaling in pulmonary arterial smooth muscle cells (PASMCs) remains comprehensively unclear. We previously found that enhanced store operated calcium entry (SOCE) and basal intracellular calcium concentration [Ca2+]i were induced by BMP4 via upregulation of TRPC1, 4 and 6 expression in PASMCs, and that BMP4 modulated TRPC channel expression through activating p38MAPK and ERK1/2 signaling pathways. In this study, BMPRII siRNA was used to knockdown BMPRII expression to investigate whether BMP4 upregulates the expression of TRPC and activating Smad1/5/8, ERK1/2 and p38MAPK pathway via BMPRII in distal PASMCs. Our results showed that knockdown of BMPRII: 1) attenuated BMP4 induced activation of P-Smad1/5/8, without altering BMP4 induced P-p38MAPK and P-ERK1/2 activation in PASMCs; 2) did not attenuate the BMP4-induced TRPC1, 4 and 6 expression; 3) did not affect BMP4-enhanced SOCE and basal [Ca2+]i. Thus, we concluded that BMP4 activated Smad1/5/8 pathway is BMPRII-dependent, while the BMP4 - ERK/p-P38 - TRPC - SOCE signaling axis are likely mediated through other receptor rather than BMPRII.
    PLoS ONE 12/2014; 9(12):e112695. DOI:10.1371/journal.pone.0112695 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neumología y Cirugía de Tórax RESUMEN. El conocimiento bio-patológico actual de la hipertensión arterial pulmonar idiopática (HAPI), se sustenta en los hallazgos patológicos de la enfermedad descritos hace más de 30 años, consistentes en importantes alteraciones morfológicas y funcionales de células endoteliales, células del músculo liso vascular pulmonar (CMLVP) y de la propia adventicia. El concepto fisiopatológico de la HAPI centrado en vasoconstricción ha cedido su lugar al de un endotelio vascular entendido como un complejo formador de una innumerable cantidad de sustancias con propiedades vasoactivas, antitrombóticas y antiproliferati-vas, cuyo desequilibrio favorece la aparición de vasoconstricción, trombosis y proliferación celular anormal. Es en base a estos conceptos que en la actualidad se considera a la HAPI como una enfermedad con carácter angioproliferativo. Palabras clave: Patobiología, hipertensión arterial pulmonar idiopática, células endoteliales, células de músculo liso vascular, proliferación vascular. ABSTRACT. Actual knowledge from cellular and molecular pathobiology of idiopathic pulmonary hypertension (IPAH) initially derived from pathological findings described more than thirty years ago. However, it is recognized now that pulmonary arterial obstruction observed at IPAH it is a multifactor problem characterized by abnormal vasoconstriction and out of control prolifera-tion from endothelial cells, smooth muscle vascular cells and altered metabolism at extra cellular matrix an adventitia causing an altered lung vascular remodeling as the hallmark of IPAH pathogenesis.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The endothelium is the orchestral conductor of blood vessel function. Pathological blood vessel formation (a process termed pathological angiogenesis) or the inability of endothelial cells (ECs) to perform their physiological function (a condition known as EC dysfunction) are defining features of various diseases. Therapeutic intervention to inhibit aberrant angiogenesis or ameliorate EC dysfunction could be beneficial in diseases such as cancer and cardiovascular disease, respectively, but current strategies have limited efficacy. Based on recent findings that pathological angiogenesis and EC dysfunction are accompanied by EC-specific metabolic alterations, targeting EC metabolism is emerging as a novel therapeutic strategy. Here, we review recent progress in our understanding of how EC metabolism is altered in disease and discuss potential metabolic targets and strategies to reverse EC dysfunction and inhibit pathological angiogenesis.
    EMBO Molecular Medicine 07/2014; DOI:10.15252/emmm.201404156 · 8.25 Impact Factor


1 Download